Results 131 to 140 of about 40,760 (162)

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Lancet, The, 2020
Peter W Horby, Marion M Mafham, Natalie Staplin   +2 more
exaly  

Ritonavir

2010
Alison Duncan, Suzanne Crowe
openaire   +1 more source

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

New England Journal of Medicine, 2020
Bin Cao, Ke Wang, Chaolin Huang
exaly  

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Lancet, The, 2020
Kwok-Cheung Lung, Tom Wai-Hin Chung, Hoi-Ping Shum   +2 more
exaly  

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

Lancet, The, 2006
Joseph J Eron, Vicente Estrada, Benjamin Young   +2 more
exaly  

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Lancet, The, 2008
Jean-Michel Molina
exaly  

Ritonavir and Lopinavir/Ritonavir

2007
openaire   +1 more source

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease

Lancet, The, 1998
D William Cameron
exaly  

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

Lancet, The, 2010
Joseph J Eron, Benjamin Young, Michael D Miller   +2 more
exaly  

Ritonavir

Reactions Weekly, 2002
openaire   +1 more source